However, the capacity of tumor cells to suppress NK cell-mediated ADCC via inducing inhibitory signals, including PD-L1 and PD-1 interaction, makes targeting PD-1 on NK cells a viable approach. The gene discussed is CD274; the disease is neoplasm.